Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Metropolis Healthcare Limited (METROPOLIS.NS)
Mumbai, IN
Metropolis Healthcare Limited functions as a prominent diagnostic service provider throughout India. The company delivers a comprehensive array of clinical laboratory testing, specialized diagnostic profiles, and associated support services. Its capabilities span diverse medical fields, encompassing oncology, neurology, gynecology, and nephrology. Furthermore, Metropolis offers a variety of health check-up packages specifically tailored for different demographic groups, including men, women, senior citizens, youth, and corporate clients. These tests are vital for disease prediction, early identification, diagnostic screening, confirmation, and continuous monitoring. Beyond its core diagnostic offerings, the company also extends its expertise to corporate wellness programs, hospital laboratory management solutions, and clinical research. As of March 31, 2022, Metropolis had established an extensive network comprising 171 clinical laboratories, 9,000 sample collection points, and 704 assisted referral centers. Founded in 1980, the company's corporate headquarters are situated in Mumbai, India.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.37% | -4.83% | +10.77% | +8.34% | +5.43% | +8.35% | +27.69% | +61.19% | -9.40% | +117.74% | +117.74% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 4 | 0 |
| Buy | 10 | 0 |
| Hold | 2 | 0 |
| Sell | 2 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Diagnostics & Research: +7.9%+23.6% ★ Q1'26: +23.0% (vs Q1'25)
-
EPS growth Medical - Diagnostics & Research: +30.8%+30.6% Q1'26: +72.9% (vs Q1'25)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%+12.4% ★ Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Medical - Diagnostics & Research: +9.6%+16.2% ★ Q1'26: +16.3% (vs Q1'25)
-
ROIC Medical - Diagnostics & Research: +5.2%+12.7% ★ Q1'26: +13.1% (vs Q1'25)
-
Share dilution Medical - Diagnostics & Research: 0.0%+0.4% Q1'26: +1.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×0.58× Q1'26: 0.54× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 17 Rev. Ana. 13 EPS Ana. |
Mar 2027 18 Rev. Ana. 16 EPS Ana. |
Mar 2028 18 Rev. Ana. 16 EPS Ana. |
Mar 2029 6 Rev. Ana. 6 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
7.61B
est: 7.61B (0.0%)
|
8.56B
est: 8.65B (-1.0%)
|
9.98B
est: 9.94B (+0.4%)
|
12.28B
est: 12.28B (+0.0%)
|
11.48B
est: 11.52B (-0.3%)
|
12.08B
est: 12.44B (-2.9%)
|
13.31B
est: 13.47B (-1.2%)
|
16.50B
16.43B – 16.70B
+22.5% YoY
|
18.92B
18.60B – 19.65B
+14.7% YoY
|
21.54B
20.87B – 22.55B
+13.8% YoY
|
24.28B
24.28B – 24.28B
+12.7% YoY
|
| EBITDA |
2.02B
est: 1.62B (+24.8%)
|
2.15B
est: 2.59B (-17.2%)
|
2.63B
est: 2.00B (+31.8%)
|
3.07B
est: 2.49B (+23.1%)
|
2.36B
est: 2.95B (-20.1%)
|
2.18B
est: 2.59B (-16.0%)
|
2.16B
est: 2.83B (-23.6%)
|
3.44B
3.42B – 3.48B
+21.4% YoY
|
3.94B
3.87B – 4.09B
+14.7% YoY
|
4.48B
4.34B – 4.69B
+13.8% YoY
|
5.06B
5.06B – 5.06B
+12.7% YoY
|
| EBIT |
1.83B
est: 1.46B (+25.5%)
|
1.94B
est: 2.23B (-13.1%)
|
2.42B
est: 1.70B (+42.3%)
|
2.82B
est: 2.12B (+32.6%)
|
2.04B
est: 2.51B (-19.0%)
|
1.95B
est: 2.18B (-10.6%)
|
1.96B
est: 2.39B (-18.0%)
|
2.90B
2.88B – 2.93B
+21.4% YoY
|
3.32B
3.26B – 3.45B
+14.7% YoY
|
3.78B
3.66B – 3.96B
+13.8% YoY
|
4.26B
4.26B – 4.26B
+12.7% YoY
|
| Net Income |
1.20B
est: 1.35B (-11.0%)
|
1.27B
est: 1.49B (-14.4%)
|
1.83B
est: 1.28B (+43.2%)
|
2.14B
est: 1.59B (+34.3%)
|
1.43B
est: 1.38B (+3.3%)
|
1.28B
est: 5.59B (-77.2%)
|
1.45B
est: 1.71B (-15.2%)
|
2.14B
2.00B – 2.29B
+25.5% YoY
|
2.99B
2.72B – 3.26B
+39.6% YoY
|
3.71B
3.27B – 4.15B
+23.9% YoY
|
4.34B
4.13B – 4.55B
+17.0% YoY
|
| SGA |
2.49B
est: 2.44B (+2.1%)
|
2.57B
est: 4.53B (-43.3%)
|
2.75B
est: 4.18B (-34.2%)
|
3.65B
est: 5.21B (-30.0%)
|
3.73B
est: 6.16B (-39.5%)
|
4.14B
est: 4.08B (+1.4%)
|
4.80B
est: 4.46B (+7.6%)
|
5.42B
5.39B – 5.48B
+21.4% YoY
|
6.21B
6.10B – 6.45B
+14.7% YoY
|
7.07B
6.85B – 7.40B
+13.8% YoY
|
7.97B
7.97B – 7.97B
+12.7% YoY
|
| EPS |
6.02
est: 26.21 (-77.1%)
|
6.34
est: 29.85 (-78.8%)
|
8.99
est: 36.42 (-75.3%)
|
10.47
est: 39.62 (-73.6%)
|
6.98
est: 29.11 (-76.0%)
|
6.24
est: 26.74 (-76.7%)
|
7.07
est: 8.17 (-13.4%)
|
10.32
9.66 – 11.07
+26.3% YoY
|
14.35
13.18 – 15.77
+39.0% YoY
|
17.30
15.80 – 20.08
+20.6% YoY
|
20.84
19.96 – 22.03
+20.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-15 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ameera Sushil Shah | Executive Chairperson | 59M | female |
| Surendran Chemmenkotil | Chief Executive Officer | 52M | male |
| Sameer Prakash Patel | Chief Financial Officer | 14M | male |
| Sushil Kanubhai Shah | Founder, Non-Executive Director & Chairman Emeritus | 7M | — |
| Kirti Chadha | Chief Scientific & Innovation Officer | — | — |
| Mohan Menon | Chief Marketing Officer | — | male |
| Pinakin Shah | Chief Information Officer | — | male |
| Kamlesh Chandrashekhar Kulkarni | Head of Legal & Secretarial and Compliance Officer | — | male |
| Jeyasingh Balakrishnan | Head of Public Relations & Corporate Communications | — | male |
| Diya Suri | Chief People Officer | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for METROPOLIS.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
